M&A
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
Капзатраты
A1 A2
IR
FY2025 Q4
В пределах ожиданий
Отчётный звонок Ingersoll Rand Inc.
Вывод Buzzberg
M&A pipeline strong with nine LOIs and capital deployment continues
Ingersoll Rand reported Q4 2025 results with orders up 8% year-over-year (1% organic) and increased its M&A activity pipeline to 9 companies under LOI. Management issued its FY2026 guidance with 2.5-4.5% total revenue growth and $1.1 billion in recurring revenue backlog. Q4 2025 organic orders grew 1% led by China and Life Sciences; management sees flat organic growth in Q1 2026.
Вывод Buzzberg M&A pipeline strong with nine LOIs and capital deployment continues Ingersoll Rand reported Q4 2025 results with orders up 8% year-over-year (1% organic) and increased its M&A activity pipeline to 9 companies under LOI. Management issued its FY2026 guidance with 2.5-4.5% total revenue growth and $1.1 billion in recurring revenue backlog. Q4 2025 organic orders grew 1% led by China and Life Sciences; management sees flat organic growth in Q1 2026. Читать полный анализСвернуть анализ
Ingersoll Rand reported Q4 2025 results with orders up 8% year-over-year (1% organic) and increased its M&A activity pipeline to 9 companies under LOI. Management issued its FY2026 guidance with 2.5-4.5% total revenue growth and $1.1 billion in recurring revenue backlog. Q4 2025 organic orders grew 1% led by China and Life Sciences; management sees flat organic growth in Q1 2026.
- FY2026 guidance expects 1% organic revenue growth at the midpoint, with M&A contributing ~1.5% and FX adding ~1%.
- Management maintains a neutral stance on macro recovery; not basing guidance on a meaningful inflection in PMI.
- Recurring revenue backlog now $1.1 billion; more confident in long-term target, though growth will be non-linear.
Выручка$2.0912BФакт
EPS$0.96Факт
Валовая маржа24.06%Факт
Операционная маржа31.73%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Recurring Revenue
Recurring revenue backlog reaches $1.1 billion
Guidance
Guidance implies no market recovery, with Q1 organic flat to down
Показать ещё 3 тезиса
Guidance
2026 EPS growth expected mid-single digit across halves
Demand
Life sciences orders up mid-teens in Q4 2025
Demand
China organic orders growth for third straight quarter
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $2.0912B | Факт |
| EPS | $0.96 | Факт |
| Валовая маржа | 24.06% | Факт |
| Операционная маржа | 31.73% | Факт |
| Свободный денежный поток | $0.4615B | Факт |
| Капзатраты | $0.0375B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2026 | $3.45–$3.57 | $3.51 | Обозначен |
| Операционная маржа | FY2026 | $2.13B–$2.19B | $2.16B | Обозначен |
| Выручка | FY2026 | 2.5%–4.5% | 3.5% | Обозначен |
AI, капзатраты и спрос
Оценка менеджмента
Cautiously Optimisti
Management highlighted positive momentum and strong execution, but adopted a prudent approach to guidance, not baking in a market recovery.
Оценка AI от менеджмента
The transcript does not discuss AI, its products, demand, or adoption.
Инвестиции и мощности
The transcript does not explicitly discuss capital expenditure, but management noted $525 million invested in 16 M&A transactions and $1 billion in share repurchases, indicating continued capital deployment focus.
все упомянутые компании ниже: 3
Компаниис момента звонка
Цепочка поставок
Цепочка поставок
Vicente Renal
China finished the year with a third consecutive quarter of positive organic order growth, while the rest of Asia was up mid-20s in Q4. — The persistent recovery in China and the rest of Asia, even without overall market growth, signals a competitive share shift and an improving demand environment for industrial equipment in the region.
Доказательства
“This marks the third quarter in a row where we saw organic water growth in China, underscoring our agility through the effective use of IRX and the success of our demand generation activities delivering consistent growth in what remains a”
Цепочка поставок
Vicente Renal
Life sciences organic order growth was mid-teens in Q4, while the aerospace and defense segment declined due to order timing and is expected to move sideways from 2025 to 2026. — A sideways aerospace business for IR contrasts with the strong demand from other aerospace suppliers, possibly pointing to different sub-segments or market share dynamics.
Доказательства
“The last piece is basically the aerospace and defense business, which is down due to order timing. Nothing unexpected as the business is generally moving sideways from 2025 to 2026.”
Внешние сигналы
Альфа цепочки поставок · 2с момента звонка
China finished the year with a third consecutive quarter of positive organic order growth, while the rest of Asia was up mid-20s in Q4.
Доказательства
“This marks the third quarter in a row where we saw organic water growth in China, underscoring our agility through the effective use of IRX and the success of our demand generation activities delivering consistent growth in what remains a…”
Life sciences organic order growth was mid-teens in Q4, while the aerospace and defense segment declined due to order timing and is expected to move sideways from 2025 to 2026.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 3. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.